Company intelligence / Profile preview
Vivet Therapeutics
Paris, Francevivet-therapeutics.com ↗
- Ownership
- Private
- Employees
- ~40
- Development stage
- Phase 2
01
Overview
Vivet Therapeutics' lead program, VTX‑801 for Wilson disease, has shown encouraging interim results in its Phase 1/2 GATEWAY trial with increased ceruloplasmin ferroxidase activity and improved liver histology. No serious adverse events have been reported so far. The company also received significant funding to advance its second program targeting CTX. Additional pipeline assets target rare inherited metabolic disorders affecting the liver.
- Therapeutic areas
- GastroenterologyMetabolic DisordersRare Diseases
- Modalities
- Gene therapy (AAV vector-based)Recombinant adeno-associated viruses (rAAVs)
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
Pfizer Inc. — manufacturing agreement, equity investment (~15%), exclusive option to acquire all shares; co-development on VTX–801/Wilson Disease program.Fundación para la Investigación Médica Aplicada/CIMA University of Navarra — technology licensing partner.Mirum Pharmaceuticals — acquired rights to develop/commercialize VTX–802 & VTX–803 in US as of 2021.BPiFrance/French government — non-dilutive grant support.Patient advocacy groups including CTX Alliance and Spanish CTX patient association.
Beyond the preview
Go deeper on Vivet Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vivet Therapeutics.